Induction of the STING-dependent DNA damage pathway by cucurbitacin B enhances immunotherapy efficacy in osteosarcoma

Articles in Press

Document Type : Original Article

Authors

1 Department of Orthopaedics, Changshu Hospital Affiliated to Nanjing University of Chinese Medicine, Changshu 215500, China

2 Department of Orthopaedics, The Third People’s Hospital of Xiangcheng District, Suzhou 215100, China

3 Institute of Traumatology & Orthopedics and Laboratory of New Techniques of Restoration & Reconstruction of Orthopedics and Traumatology, Nanjing University of Chinese Medicine, Nanjing, 210023, China

4 Department of Traumatology & Orthopedics, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210004, China

10.22038/ijbms.2025.86376.18663

Abstract

Objective(s): Osteosarcoma (OS) is a highly aggressive bone tumor with limited therapeutic options. Cucurbitacin B (CuB), a natural compound derived from Cucurbitaceae plants, has demonstrated antitumor activity in various malignancies; however, its mechanisms in OS remain unclear. This study aims to elucidate the antitumor effects of CuB in OS and explore its molecular mechanisms. 
Materials and Methods: MG63 and K7M2 OS cells were treated with CuB, and cell viability was assessed using the cell counting kit-8 (CCK8) assay. Colony formation assays were employed to evaluate proliferation, while flow cytometry was used to analyze apoptosis and cell cycle distribution. DNA damage was determined by immunofluorescence staining and comet assay. Western blotting was used to detect proteins involved in activating the stimulator of the interferon genes (STING) pathway. In vivo OS xenograft models were established to monitor tumor growth and immune responses, and the therapeutic efficacy of combination treatment with anti-programmed death-ligand 1 (PD-L1) was evaluated.
Results: CuB inhibited OS cell proliferation, induced apoptosis, and caused G2/M cell cycle arrest. It activated the STING pathway and induced DNA damage. In vivo, CuB reduced tumor growth and metastasis, enhanced CD8+ and CD4+ T cell infiltration, and reduced regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). Combination with anti-PD-L1 further suppressed tumor growth. 
Conclusion: CuB exerts anti-OS effects by inducing DNA damage, activating the STING pathway, enhancing immune responses, and synergizing with anti-PD-L1, highlighting its therapeutic potential.

Keywords

Main Subjects

References

1. Cersosimo F, Lonardi S, Bernardini G, Telfer B, Mandelli GE, Santucci A, et al. Tumor-associated macrophages in osteosarcoma: From mechanisms to therapy. Int J Mol Sci 2020; 21: 5207-5227.
2. Panez-Toro I, Munoz-Garcia J, Vargas-Franco JW, Renodon-Corniere A, Heymann MF, Lezot F, et al. Advances in osteosarcoma. Curr Osteoporos Rep 2023; 21:330-343.
3. Shoaib Z, Fan TM, Irudayaraj J. Osteosarcoma mechanobiology and therapeutic targets. Brit J Pharmacol 2022; 179: 201-217.
4. Su Q, Xu B, Tian Z, Gong Z. 1,3,5-triazines inhibit osteosarcoma and avert lung metastasis in a patient-derived orthotopic xenograft mouse model with favorable pharmacokinetics. Iran J Basic Med Sci 2022; 25: 295-301.
5. Meltzer PS, Helman LJ. New horizons in the treatment of osteosarcoma. New Engl J Med 2021; 385: 2066-2076.
6. Ding X, Lu D, Fan J. A natural product phillygenin suppresses osteosarcoma growth and metastasis by  regulating the SHP-1/JAK2/STAT3 signaling. Biosci Biotech Bioch 2021; 85: 307-314.
7. Yuan R, Zhao W, Wang QQ, He J, Han S, Gao H, et al. Cucurbitacin B inhibits non-small cell lung cancer in vivo and in vitro by triggering TLR4/NLRP3/GSDMD-dependent pyroptosis. Pharmacol Res 2021; 170: 105748-105763.
8. Dai S, Wang C, Zhao X, Ma C, Fu K, Liu Y, et al. Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics. Pharmacol Res 2023;187: 106587-106607.
9. Wei J, Chen X, Li Y, Li R, Bao K, Liao L, et al. Cucurbitacin B-induced G2/M cell cycle arrest of conjunctival melanoma cells mediated by GRP78-FOXM1-KIF20A pathway. Acta Pharm Sin B 2022; 12: 3861-3876.
10. Yuan R, Fan Q, Liang X, Han S, He J, Wang QQ, et al. Cucurbitacin B inhibits TGF-beta1-induced epithelial-mesenchymal transition (EMT) in NSCLC through regulating ROS and PI3K/Akt/mTOR pathways. Chin Med 2022; 17: 24-40.
11. Zhang H, Zhao B, Wei H, Zeng H, Sheng D, Zhang Y. Cucurbitacin B controls M2 macrophage polarization to suppresses metastasis via targeting JAK-2/STAT3 signalling pathway in colorectal cancer. J Ethnopharmacol 2022; 287: 114915.
12. Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, et al. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 2009; 69: 5876-5884.
13. Lee DH, Thoennissen NH, Goff C, Iwanski GB, Forscher C, Doan NB, et al. Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. Cancer Lett 2011; 306: 161-170.
14. Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutagen 2017; 58: 235-263.
15. Nassiri-Asl M, Ghorbani A, Salehisar S, Asadpour E, Sadeghnia HR. Effect of rutin on oxidative DNA damage in PC12 neurons cultured in nutrients deprivation condition. Iran J Basic Med Sci 2020; 23: 390-395.
16. Sadoughi F, Maleki DP, Asemi Z, Yousefi B. DNA damage response and repair in osteosarcoma: Defects, regulation and  therapeutic implications. DNA Repair 2021; 102: 103105.
17. Samson N, Ablasser A. The cGAS-STING pathway and cancer. Nat Cancer 2022; 3: 1452-1463.
18. Chen C, Xu P. Cellular functions of cGAS-STING signaling. Trends Cell Biol 2023; 33: 630-648.
19. Hopfner KP, Hornung V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat Rev Mol Cell Bio 2020; 21: 501-521.
20. Wu Y, Chen W, Xu ZP, Gu W. PD-L1 Distribution and perspective for cancer immunotherapy-blockade, knockdown,  or inhibition. Front Immunol 2019; 10: 2022-2037.
21. Oghalaie A, Mahboudi F, Rahimi-Jamnani F, Piri-Gavgani S, Kazemi-Lomedasht F, Hassanzadeh Eskafi A, et al. Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate. Iran J Basic Med Sci 2022; 25: 313-319.
22. Zhou Y, Yang Q, Dong Y, Ji T, Zhang B, Yang C, et al. First-in-maintenance therapy for localized high-grade osteosarcoma: An open-label  phase I/II trial of the anti-PD-L1 antibody ZKAB001. Clin Cancer Res 2023; 29: 764-774.
23. Tang Z, Zhao L, Yang Z, Liu Z, Gu J, Bai B, et al. Mechanisms of oxidative stress, apoptosis, and autophagy involved in graphene oxide nanomaterial anti-osteosarcoma effect. Int J Nanomed 2018; 13: 2907-2919.
24. Jiang H, Zhao X, Zang J, Wang R, Gao J, Chen J, et al. Establishment of a prognostic risk model for osteosarcoma and mechanistic investigation. Front Pharmacol 2024; 15: 1399625-1399640.
25. Chittasupho C, Samee W, Na Takuathung M, Okonogi S, Nimkulrat S, Athikomkulchai S. Clerodendrum chinense stem extract and nanoparticles: Effects on proliferation, colony formation, apoptosis induction, cell cycle arrest, and mitochondrial membrane potential in human breast adenocarcinoma breast cancer cells. Int J Mol Sci 2024; 25: 978-1003.
26. Ma Q, Li X, Wang H, Xu S, Que Y, He P, et al. HOXB5 promotes the progression and metastasis of osteosarcoma cells by activating the JAK2/STAT3 signalling pathway. Heliyon 2024; 10: e30445-459.
27. Li J, Jiang W, Shan W, Luo A, Qu G, Zhang J, et al. The synergistic anticancer effect of CBD and DOX in osteosarcoma. Clin Transl Oncol 2023; 25: 2408-2418.
28. Lu Y, Liu Y, Yang C. Evaluating in vitro DNA damage using comet assay. J Vis Exp 2017; 128: 56450-56456.
29. Carlsson MJ, Vollmer AS, Demuth P, Heylmann D, Reich D, Quarz C, et al. p53 triggers mitochondrial apoptosis following DNA damage-dependent replication stress by the hepatotoxin methyleugenol. Cell Death Dis 2022; 13: 1009-1024.
30. Kwon J, Bakhoum SF. The cytosolic dna-sensing cGAS-STING pathway in cancer. Cancer Discov 2020; 10: 26-39.
31. Goldstein M, Kastan MB. The DNA damage response: Implications for tumor responses to radiation and  chemotherapy. Annu Rev Med 2015; 66: 129-143.
32. Reislander T, Groelly FJ, Tarsounas M. DNA damage and cancer immunotherapy: A STING in the tale. Mol Cell 2020; 80: 21-28.
33. Yang K, Han W, Jiang X, Piffko A, Bugno J, Han C, et al. Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration. Nat Nanotechnol 2022; 17: 1322-1331.
34. Fang L, Tian W, Zhang C, Wang X, Li W, Zhang Q, et al. Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma. Pharmacol Res 2023; 189: 106701-106714.
35. Ding L, Qian J, Yu X, Wu Q, Mao J, Liu X, et al. Blocking MARCO(+) tumor-associated macrophages improves anti-PD-L1 therapy of hepatocellular carcinoma by promoting the activation of STING-IFN type I pathway. Cancer Lett 2024; 582: 216568.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 11 June 2025

Files

Share

How to cite

Statistics